Suppr超能文献

原位睾丸癌中免疫组化肿瘤标志物表达的异质性:发病机制相关性

Heterogeneity of expression of immunohistochemical tumour markers in testicular carcinoma in situ: pathogenetic relevance.

作者信息

Rajpert-De Meyts E, Kvist M, Skakkebaek N E

机构信息

Department of Growth and Reproduction, Juliane Marie Centre, National University Hospital, Copenhagen, Denmark.

出版信息

Virchows Arch. 1996 Jun;428(3):133-9. doi: 10.1007/BF00200655.

Abstract

Testicular carcinoma in situ (CIS) is the precursor of germ cell tumours in adults, except for spermatocytic seminoma. The mechanism of the progression from premalignant CIS to invasive and overt tumours is largely unknown. There are currently two main hypotheses: one is that CIS can progress directly to either seminoma or nonseminoma; according to the other, seminoma is the intermediate stage between CIS and nonseminoma. CIS cells express several tumour antigens, such as placental-like alkaline phosphatase (PLAP), TRA-1-60, or the c-kit proto-oncogene protein product (Kit), which are present to varying degrees in the invasive germ cell tumours. In this study, CIS cells adjacent to either pure or combined tumours were examined by double immunohistochemical staining for simultaneous expression of TRA-1-60 (typical for embryonal carcinoma) and either Kit (expressed by seminomas) or PLAP (found mainly in seminomas, but also in some cases of nonseminoma). Marked differences in the expression of these antigens were found among CIS cells, especially those adjacent to mixed tumours. We conclude that CIS is a phenotypically heterogeneous lesion, and that the CIS cells, despite identical morphology and close spatial localization, may be in different stages of progression. The results lend support to the hypothesis that CIS can progress directly to both seminomatous and nonseminomatous tumours.

摘要

睾丸原位癌(CIS)是成人生殖细胞肿瘤(精母细胞性精原细胞瘤除外)的前驱病变。从癌前CIS进展为浸润性明显肿瘤的机制在很大程度上尚不清楚。目前有两种主要假说:一种是CIS可直接进展为精原细胞瘤或非精原细胞瘤;另一种观点认为,精原细胞瘤是CIS和非精原细胞瘤之间的中间阶段。CIS细胞表达多种肿瘤抗原,如胎盘样碱性磷酸酶(PLAP)、TRA-1-60或c-kit原癌基因蛋白产物(Kit),这些抗原在浸润性生殖细胞肿瘤中不同程度地存在。在本研究中,通过双重免疫组织化学染色检查与纯肿瘤或混合肿瘤相邻的CIS细胞,以同时检测TRA-1-60(胚胎性癌的典型标志物)和Kit(精原细胞瘤表达)或PLAP(主要见于精原细胞瘤,但在某些非精原细胞瘤病例中也有发现)的表达。在CIS细胞中发现了这些抗原表达的显著差异,尤其是那些与混合肿瘤相邻的细胞。我们得出结论,CIS是一种表型异质性病变,并且CIS细胞尽管形态相同且空间定位紧密,但可能处于不同进展阶段。这些结果支持了CIS可直接进展为精原细胞瘤和非精原细胞瘤的假说。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验